Articles

  • 3 weeks ago | uk.marketscreener.com | Aidan Lane

    Milton Capital PLC - Special purpose acquisition company seeking opportunities in the energy sector - Agrees to extended exclusivity agreement for the potential acquisition of certain Horizon Energy Global Corp subsidiaries until the end of May. The companies had in February extended the agreement until the end of March. The energy transition company Horizon seeks to divest its European assets from its core North American domestic business.

  • 3 weeks ago | marketscreener.com | Aidan Lane

    Block Energy PLC - Georgia-focused oil and gas company - Announce the acquisition of a 10% participating interest in the XIQ Production Sharing Contract in Georgia. The deal has an option to increase to 22%. The site is "highly prospective," and contains mean unrisked recoverable prospective resources of 451.5 million barrels of oil and 823.3 billion cubic feet of gas. Company says its key target is the Martkopi Terrace prospect with 267.2 mmbbl mean unrisked recoverable prospective resources.

  • 1 month ago | in.marketscreener.com | Aidan Lane

    (Alliance News) - Carnival PLC & Corp on Friday reported stronger first quarter earnings backed by an uptick in net yields. The Miami, Florida-based cruise operator said first quarter revenue in the three months to February 28 rose 7.4% to USD5.81 billion from USD5.41 billion a year prior. Of this, passenger ticket revenue grew 5.8% to USD3.83 billion from USD3.62 billion a year prior. Onboard and other revenue was USD1.98 billion, up 11% from USD1.79 billion.

  • 1 month ago | uk.marketscreener.com | Aidan Lane

    FirstGroup PLC - Aberdeen, Scotland-based public transport provider - Completes buyback of 30.4 million shares worth a total of GBP50.0 million, which began November 15. The average price of shares bought back under the programme was 163.94 pence.

  • 1 month ago | uk.marketscreener.com | Aidan Lane

    Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - The new drug application for Tazverik has been granted conditional approval by the National Medical Products Administration in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with the EZH2 gene mutation who have received at least two prior systemic therapies.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map